Synairgen Aims To Disprove Doubts About Interferon Therapy In COVID-19
Nebulized Formulation ‘Is Key’
The UK company surged on early results in the summer – but must prove its therapy’s impact in a Phase III study
The UK company surged on early results in the summer – but must prove its therapy’s impact in a Phase III study